ACTA negotiates and advocates on behalf of the clinical trials sector with governments, health care policymakers and consumers on issues that impact the conduct of investigator-initiated clinical trials across the Australian health system.
Greater engagement and partnership between policymakers and clinical researchers significantly improves the process of generating high-quality evidence for new and existing clinical therapies at low marginal cost or with cost-savings.
ACTA represents the sector across many National and International Committees. At this time, these include:
- Clinical Trials – Phase 2 Advisory Committee (Advisory Committee): working with the Australian Commission on Safety and Quality in Health Care on the development and pilot of the National Clinical Trials Governance Framework.
- Working together with government, policymakers and consumers
ACTA is the peak body for clinical trial networks, clinical quality registries and clinical trial coordinating centres in Australia. We represent the investigator-initiated clinical trials sector.
Latest Resources
-
-
ACTA 2020-2021 Annual Report
-
ACTA Whistleblower Policy
-
Official Opening of the 2020 ACTA Summit: Minister’s Address
-
ACTA submission: Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia
-
ACTA Constitution
-
Media Release: Australian Clinical Trials Alliance commends the Health Minister’s vision to expedite clinical trials in Australia
-
ACTA Trial of the Year Award 2020 guidelines and nomination forms
-
ACTA Year in Review: Financial Year 2018-2019
-
ACTA activity work plan 2019 – 2020
-
Report on the activities and achievements of clinical trials networks in Australia 2004 – 2014
-
Submission to MRFF Consultation
-
Submission to Medical Research Future Fund Priority Consultation
-
Medical Research Future Fund – clinical trial funding set to deliver significant benefits to Australian patients and the economy
-
ACTA Advisory Council minutes July 2017
-
Economic evaluation of investigator-initiated clinical trials conducted by networks
-
Opportunities for linking evidence development to reimbursement in Australia
-
Clinical Quality Registries: A national approach
-
How can clinical trials networks drive better translation of evidence into better quality care?
-
The Global Perspective: Measuring the impact of Australian-led trials & registries internationally
-
ACTA Summit 2016 – Opening address
-
ACTA Submission to the NHMRC Public Consultation on revisions to sections 3 & 5 of the National Statement
-
ACTA Summit 2016 – Dr Neil Soderlund
-
Medical Research Future Fund set to put high quality evidence at the heart of healthcare – historic moment for all Australians
-
ACTA Submission to the NHMRC Structural Review
-
ACTA Submission on the MRFF Strategy & Priorities
-
ACTA Submission on the National Safety and Quality Health Service Standards Version 2: Consultation Draft
-
ACTA Submission to the Medicare Benefits Schedule Review Taskforce
-
ACTA Submission to the Community Affairs Legislation Committee on the Medical Research Future Fund Bill 2015
-
ACTA submission on safety monitoring & reporting of clincial trials in Australia
-
ACTA Submission to The Independent Hospital Pricing Authority (IHPA) Teaching, Training and Research Costing Study
-
ACTA Submission on draft Principles for accessing and using publicly funded data for health research
-
WA Health joins national alliance for better evidence in healthcare
-
ACTA submission on revised table of standard costs for clinical trials
-
Report on the ACTA 2014 National Summit of Clinical Trials Networks
-
ACTA submission to the ACSQHC on variation in healthcare
Latest News
-
New MRFF Strategy and Priorities released
-
ACTA welcomes inquiry findings into the approval processes for new drugs and novel medical technologies in Australia
-
Research Australia web consultation
-
ACSQHC – National One-Stop-Shop Survey
-
Clinical Trials – Phase 2 Advisory Committee Communique – Meeting 6, 1 October 2021
-
National Clinical Trials Governance Framework Pilot: Update
-
National One-Stop-Shop
-
White Coats Foundation: Power of One Campaign
-
Parliamentary Inquiry into approval processes for new drugs and novel medical technologies in Australia
-
ARDC HeSANDA Australian Data Partnerships Program: Open Call
-
Continuity of Care Collaboration (CCC) Forum – Rural and Remote Health
-
Media Release: Australian Clinical Trials Alliance commends the Health Minister’s vision to expedite clinical trials in Australia
-
ACTA STInG: signatories to open letters addressing statistical analysis and data integrity in COVID-19 publications
-
Australian Clinical Trials Alliance celebrating and honouring clinical trials on International Clinical Trials Day
-
National Medical Stockpile: Supply of experimental medicines to support clinical trials
-
Tweetchats with PRAXIS and ACTA
-
ACTA statement on COVID-19
-
Nominations extended for ACTA Trial of the Year Awards
-
ACTA—a year in review, 2018-2019 financial year
-
ACTA announces new Board: productive diversity
Latest Events
-
Sector consultations – online discussion with ACTA
-
Clinical Trials 2021: National Tribute and Award Ceremony
-
Clinical Trials 2020: National Tribute and Award Ceremony
-
ACTA Advisory Council Meeting
-
Continuity of Care Collaboration (CCC) Forum – Rural and Remote Health
-
ARDC HeSANDA Australian Data Partnerships Program: Open Call